Shares of CNS Pharmaceuticals Inc. (NASDAQ:CNSP) slipped 2.8% on Wednesday after the company disclosed that its Chief Executive Officer, John Climaco, has stepped down from the role.
The biopharmaceutical firm, which develops therapies targeting primary and metastatic cancers of the brain and central nervous system, announced that Rami Levin has been appointed President and Chief Executive Officer, effective January 1, 2026.
Levin brings close to three decades of international leadership experience spanning several therapeutic areas, including oncology and neurology. His career includes senior executive positions at companies such as Saniona and ImStem Biotechnology, where he led strategic transformations and raised substantial financing.
“We are grateful to John and his dedicated service to CNS Pharmaceuticals and wish him all the best in his next endeavors,” said Faith Charles, Chair of the Board of Directors. She added that Levin’s “combination of scientific depth, commercial execution, and capital markets expertise” positions him well to guide the company into its next phase of growth.
Earlier in his career, Levin demonstrated a strong track record of scaling organizations, most notably at Sobi, where he expanded the North American business into the company’s largest and most profitable region, increasing revenue from roughly $46 million to more than $500 million.
Levin holds an MBA from Tel Aviv University’s Recanati Business School and has completed executive education programs at institutions including INSEAD and Northwestern University’s Kellogg School of Management.